Selank

Clinical trials observed no tolerance, dependence, or withdrawal with Selank use. Because Selank modulates the existing GABA system rather than artificially forcing receptor activity, the brain does not compensate by downregulating GABA receptors. This is in stark contrast to benzodiazepines, which cause tolerance, physical dependence, and withdrawal.

A clinical trial by Medvedev et al. (2014) compared Selank to Phenazepam (a Russian benzodiazepine) and found comparable anxiety reduction. Notably, the anxiolytic effect from Selank persisted for up to one week after the last dose, suggesting it produces lasting systemic changes rather than merely masking symptoms. Selank had no objectionable side effects and positively impacted patient quality of life.

A clinical trial by Zozulya et al. (2008) compared Selank directly to Medazepam (a benzodiazepine commonly used in Russia). Anxiolytic effects were similar between the two, but Selank also demonstrated anti-fatigue and mild psychostimulant effects that Medazepam did not, meaning it improved energy and mental clarity on top of anxiety reduction.

Research by Kassian et al. (2017) showed Selank enhances the anxiolytic effect of GABA signaling through a different binding mechanism than benzodiazepines. Rather than forcing GABA-A receptors to open more aggressively, Selank acts as a positive allosteric modulator, making the brain's existing GABA production work more effectively. This avoids receptor downregulation, tolerance, and dependence.

Selank has been demonstrated in both human and animal studies to reduce anxiety and stress without causing the drowsiness, tolerance, or dependence commonly associated with benzodiazepines. Users experience calm focus rather than mental flattening or sedation. This positions Selank as a potentially safer anxiolytic alternative for those seeking anxiety relief without the side effect profile of traditional pharmacological options.

Selank has been used in Russia as a prescription medication for over two decades and has been on their official list of vital and essential medicines since 2011. It is approved for generalized anxiety disorder and neurasthenia.

Selank is proposed to interact with stress response systems, potentially buffering against the cognitive and physiological toll of chronic stress. Specific effects noted include reduction of cortisol spikes and improvement in overall composure. The mechanistic basis involves Selank's interaction with the body's stress response pathways, though the precise evidence tier for cortisol effects is not fully specified in this excerpt.

Selank inhibits the enzymes that break down the body's natural enkephalin-regulating peptides. By slowing their degradation, Selank may help endogenous regulatory peptides stay active for longer, contributing to a multi-layered therapeutic effect.

Beyond GABA modulation, Selank influences monoamine neurotransmitters including serotonin, dopamine, and norepinephrine. This monoamine modulation may contribute to the mood and focus improvements reported by users beyond just anxiety reduction.

Selank upregulates brain-derived neurotrophic factor (BDNF), particularly in the hippocampus. BDNF supports neuron survival, neurogenesis, and synaptic plasticity. Since chronic anxiety suppresses BDNF and low BDNF worsens anxiety, Selank may help break this negative cycle by simultaneously calming GABA signaling and supporting the brain's ability to adapt and recover.

A 2016 study by Volkova confirmed that Selank changes the expression of 45 out of 84 genes involved in GABA function in the brain. The pattern of gene expression changes matched what occurred when GABA itself was administered, and these changes were observed within 1 hour of administration.

The speaker outlines a structured three-domain framework for peptide use in perimenopausal women: (1) metabolic system — tirzepatide or retatrutide for weight and appetite control; (2) sleep quality — selank or DSIP for anxiety and sleep; (3) growth hormone axis — tesamorelin or CJC-1295 for GH support. This represents the only explicit stacking/protocol structure in the video. No dosages, frequencies, or cycling protocols are provided for any of the three domains.

The speaker makes a broad protocol-level finding that all peptide interventions in perimenopause are symptomatic management tools and should only be introduced as a 'second layer' after the underlying hormonal deficiency (progesterone first, then estrogen) has been addressed. Using peptides without correcting the progesterone-estrogen ratio is characterized as insufficient. This represents a stacking and sequencing recommendation applicable to all peptides discussed in the video.

Selank is recommended to address perimenopause-related anxiety and sleep disruption. The speaker identifies anxiety and poor sleep as downstream consequences of the progesterone-estrogen ratio imbalance. No dosage, route of administration, or frequency is specified. It is presented as a symptomatic intervention rather than a hormonal solution.

All human clinical data on Selank comes from Russian studies. There are no published Western clinical trials as of the video's recording. Sample sizes are smaller than what would typically be required for FDA approval. The speaker acknowledges the evidence is promising but notes this limitation in evidence depth compared to more established compounds.

Selank has a minimal side effect profile. The most common side effects are mild nasal irritation from the spray and occasional mild headache. No sedation, cognitive impairment, or motor coordination effects are reported. Contraindications include pregnancy/breastfeeding, concurrent use of MAO inhibitors, and uncontrolled psychiatric conditions such as mania. Long-term safety data is not fully established by Western standards.

Selank is primarily administered intranasally (nasal spray or drops) as it crosses the blood-brain barrier directly through nasal passages. Subcutaneous injection is also possible for more precise dosing. Oral administration is not viable due to stomach acid degradation. Typical dosing is 150-300 micrograms intranasally, two to three times per day, with protocols running 2-4 weeks on followed by 2-4 weeks off.

Selank is a seven amino acid peptide derived from Tuftsin, a naturally occurring four amino acid fragment of human immunoglobulin G (IgG). Researchers at the Institute of Molecular Genetics at the Russian Academy of Sciences in the 1990s extended Tuftsin by three amino acids to improve stability and blood-brain barrier penetration. The result retained Tuftsin's immune modulating properties while gaining anxiolytic effects.

Many users of Selank self-report sharper focus, improved ability to process information under pressure, and reduced mental fatigue. Laboratory studies also show improvements in cognitive task performance, particularly under stressful conditions. No specific dosages or protocols are mentioned in this excerpt.